Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Capital Expenditures (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Capital Expenditures for 6 consecutive years, with $93000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures changed N/A to $93000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $104000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $104000.0 for FY2025, 845.45% up from the prior year.
  • Capital Expenditures for Q4 2025 was $93000.0 at Actinium Pharmaceuticals, up from $11000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $270000.0 in Q2 2022, with the low at $4000.0 in Q1 2021.
  • Average Capital Expenditures over 5 years is $63000.0, with a median of $54000.0 recorded in 2021.
  • The sharpest move saw Capital Expenditures skyrocketed 985.71% in 2023, then plummeted 85.53% in 2024.
  • Over 5 years, Capital Expenditures stood at $68000.0 in 2021, then plummeted by 76.47% to $16000.0 in 2022, then soared by 87.5% to $30000.0 in 2023, then tumbled by 63.33% to $11000.0 in 2024, then soared by 745.45% to $93000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $93000.0, $11000.0, and $30000.0 for Q4 2025, Q1 2024, and Q3 2023 respectively.